NCT05172700 2024-12-18Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerEli Lilly and CompanyApproved for marketing
NCT00068146 2018-07-05Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated LymphomaNational Institutes of Health Clinical Center (CC)Completed77 enrolled